Doctor Turns Against Messenger RNA COVID-19 Vaccines, Calls for Global Pause

A doctor who promoted COVID-19 vaccines is now calling for health authorities around the world to pause the administration of two of the most-widely utilized COVID-19 vaccines, saying that the benefits from the vaccines may not outweigh the risks. "There is more than enough evidence—I would say the evidence is overwhelming—to pause the rollout of the vaccine," Dr. Aseem Malhotra, a British cardiologist and evidence-based medicine expert, told The Epoch Times. A paper from Malhotra detailing the evidence was published on Sept. 26. Among the citations is a recent reanalysis of the Pfizer and Moderna clinical trials that concluded that vaccinated trial participants were at higher risk of serious adverse events. He called the study a "smoking gun." Malhotra also pointed to the lack of reduction in mortality or severe disease in the trials, which were completed in 2020. Taking into account death rates and other figures since then, the number of people who need to be vaccinated to prevent a single COVID-19 death ranges from 93,000 for people aged 18–29 to 230 for people aged 80 and older, according to an analysis of UK safety and effectiveness data by the Health Advisory & Recovery Team. The author also noted that serious side effects have been detected after the trials, such as myocarditis, a form of heart inflammation. Overall, looking at the absolute benefits and drawbacks of the vaccines, it's time to halt their usage and allow authorities and other experts to closely examine the data to see if the vaccines should be used again down the road, according to Malhotra. The paper was published in the Journal of Insulin Resistance in two parts following peer review. Pfizer and Moderna didn't return requests for comment. Reversal of Opinion Malhotra received the Pfizer primary series in January 2021. He became a promoter of the vaccine, even appearing on "Good Morning Britain" to advise Indian film director Gurinder Chadha to get the vaccine. Chadha did so shortly after. Malhotra said he began digging into vaccine data after his father, Dr. Kailash Chand, suffered a cardiac arrest at home approximately six months after receiving Pfizer's vaccine. The post-mortem showed two of Chand's major arteries were severely blocked, even though Malhotra described his father as a fit person who didn't have any significant heart problems. Malhotra began reading about post-vaccination issues, including a study abstract in the journal Circulation that identified a higher risk of a heart attack following vaccination with the Pfizer and Moderna vaccines and a study from Nordic countries that identified a higher risk of myocarditis. While authorities have claimed that myocarditis is more common after COVID-19 than vaccination, many studies have found otherwise, at least for certain age groups. Some papers have found no increased incidence of heart inflammation for COVID-19 patients. Malhotra has come to believe that his father's death was linked to the vaccine. "I've always approached medicine and science with uncertainties because things constantly evolve. And the information I had at the time is completely different to the information I have now," Malhotra told The Epoch Times. "And in fact, it is my duty and responsibility as the information has changed to act on that information. And that's what I'm doing." Response to Criticism After the new paper was published, critics noted that Malhotra is a board member of the Journal of Insulin Resistance. He acknowledged the position but said the article went through an independent peer review process and that he has no financial links to the journal. The doctor encouraged people to view his publication history, which includes articles in the British Medical Journal and the Journal of the American Medical Association. He said he chose to submit the paper to the insulin journal for several reasons, including it being "one of the few journals that doesn't take money from the pharmaceutical industry." "I don't think that there's any validity to question the integrity of the piece," he s